C N Landen - JoVE Visualize

Showing results (1-10 of 6) with videos related to

Pageof 1

Sort By:

Seminars in Perinatology|September 20, 2001

Prostaglandin inhibitors as tocolytic agentsS T Vermillion, C N Landen

American Journal of Obstetrics and Gynecology|May 12, 2001

Differing mechanisms of inhibition of calcium increases in human uterine myocytes by indomethacin and nimesulideC N Landen, P Zhang, R C Young

Thrombosis and Haemostasis|May 1, 1997

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia BD Liles, C N Landen, D M Monroe, et al.

Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogsM A Kay, C N Landen, S R Rothenberg, et al.

Science (New York, N.Y.)|October 1, 1993

In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.

Human Gene Therapy|August 1, 1995

Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expressionB Fang, R C Eisensmith, H Wang, et al.

Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:

Pageof 1

Seminars in Perinatology|September 20, 2001

Prostaglandin inhibitors as tocolytic agentsS T Vermillion, C N Landen

American Journal of Obstetrics and Gynecology|May 12, 2001

Differing mechanisms of inhibition of calcium increases in human uterine myocytes by indomethacin and nimesulideC N Landen, P Zhang, R C Young

Thrombosis and Haemostasis|May 1, 1997

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia BD Liles, C N Landen, D M Monroe, et al.

Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogsM A Kay, C N Landen, S R Rothenberg, et al.

Science (New York, N.Y.)|October 1, 1993

In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.

Human Gene Therapy|August 1, 1995

Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expressionB Fang, R C Eisensmith, H Wang, et al.

Pageof 1